The MATTERS Trial: Safety and Tolerability of Whole-Body Hyperthermia at 41.50°C in Combination with Chemotherapy in Metastatic Cancer Patients

The MATTERS trial demonstrates that WBHT at 41.50°C, delivered with the TempoCure device, is a safe and well-tolerated treatment for advanced malignancies, particularly in patients with refractory metastatic PDAC. These findings support the integration of WBHT with standard chemotherapy regimens, paving the way for future efficacy trials aimed at improving therapeutic outcomes in challenging cancer populations.